Kelun-Biotech Highlights ADC Pipeline, Global Ambitions at JPM Healthcare Conference
Event summary
- Kelun-Biotech showcased its ADC and novel drug conjugate (DC) pipeline at the JPM Healthcare Conference on January 15, 2026.
- The company has two ADC products on the market (sacituzumab tirumotecan and trastuzumab botidotin) and nine ADC/DC drugs in clinical stages.
- Results from the OptiTROP-Lung04 study of sac-TMT were published in The New England Journal of Medicine.
- Kelun-Biotech has five commercialized products in China, three of which are on the National Reimbursement Drug List (NRDL).
The big picture
Kelun-Biotech's emergence as a leader in China's innovative drug field, particularly in ADCs, reflects the broader trend of increased investment and innovation within the Chinese biopharmaceutical sector. The company's focus on high-incidence cancers aligns with China's growing healthcare needs and government support for domestic drug development. The partnership with MSD signals an ambition to compete on a global scale, but also introduces dependencies and potential IP-related risks.
What we're watching
- Globalization
- The success of Kelun-Biotech's collaborations with MSD and other partners will be critical for its international expansion and ability to recoup R&D investments.
- Clinical Execution
- The pace of clinical trial enrollment and data readouts for the nine pivotal studies in China will dictate the timeline for potential market expansion and revenue growth.
- Platform Risk
- While the OptiDC™ platform is a key differentiator, its ability to consistently generate novel, effective ADC/DC candidates will determine Kelun-Biotech’s long-term competitive advantage.
Related topics